AI Engines For more Details: Perplexity Kagi Labs You
Nausea and Vomiting: Homochlorcyclizine dihydrochloride is primarily used as an antiemetic to prevent or alleviate nausea and vomiting associated with various conditions, including motion sickness, post-operative nausea and vomiting, chemotherapy-induced nausea and vomiting, and other gastrointestinal disorders.
Allergic Conditions: As an antihistamine, homochlorcyclizine dihydrochloride may also be used to relieve symptoms of allergic conditions such as allergic rhinitis (hay fever), allergic conjunctivitis (eye allergies), and allergic skin reactions (such as hives or urticaria).
Motion Sickness: Homochlorcyclizine dihydrochloride may be prescribed to prevent motion sickness, particularly during travel by car, boat, or airplane. It works by blocking histamine receptors in the brain, which helps reduce nausea and vomiting associated with motion sickness.
Pruritus (Itching): Due to its antihistaminic effects, homochlorcyclizine dihydrochloride may also be used to relieve itching associated with allergic reactions, insect bites, or other skin conditions.
Vertigo: In some cases, homochlorcyclizine dihydrochloride may be prescribed to alleviate symptoms of vertigo, a sensation of spinning or dizziness that can occur due to inner ear problems or other causes.
Off-Label Uses: There may be other off-label uses for homochlorcyclizine dihydrochloride, depending on the clinical judgment of healthcare providers. These could include adjunctive treatment for certain psychiatric conditions, such as anxiety or insomnia, although evidence for such uses may be limited.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| species | Parabacteroides distasonis | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.8 | 0.8 | |
| Acne | 0.3 | 0.3 | 0 |
| ADHD | 4.3 | 0.6 | 6.17 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 2.7 | 2.7 | 0 |
| Allergies | 6.3 | 4 | 0.57 |
| Allergy to milk products | 1.3 | 1.6 | -0.23 |
| Alopecia (Hair Loss) | 1.6 | 1.6 | |
| Alzheimer's disease | 6.4 | 5.4 | 0.19 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 4.3 | 1.3 | 2.31 |
| Ankylosing spondylitis | 4.3 | 0.7 | 5.14 |
| Anorexia Nervosa | 1.1 | 2.6 | -1.36 |
| Antiphospholipid syndrome (APS) | 0.9 | 0.3 | 2 |
| Asthma | 4.8 | 3.3 | 0.45 |
| Atherosclerosis | 1.5 | 2.6 | -0.73 |
| Atrial fibrillation | 3.3 | 2.7 | 0.22 |
| Autism | 8.5 | 9.7 | -0.14 |
| Autoimmune Disease | 1.2 | 0.8 | 0.5 |
| Barrett esophagus cancer | 0.3 | 0.3 | 0 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 1.2 | 1.2 | |
| Bipolar Disorder | 1.9 | 1.1 | 0.73 |
| Brain Trauma | 0.9 | 1.1 | -0.22 |
| Breast Cancer | 0.4 | 0.4 | |
| Cancer (General) | 0.6 | 2.6 | -3.33 |
| Carcinoma | 4 | 2.3 | 0.74 |
| Celiac Disease | 2.4 | 3.9 | -0.63 |
| Cerebral Palsy | 1.6 | 1 | 0.6 |
| Chronic Fatigue Syndrome | 3.2 | 5.9 | -0.84 |
| Chronic Kidney Disease | 4 | 2.4 | 0.67 |
| Chronic Lyme | 0.6 | 0.8 | -0.33 |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.1 | 1.4 | -0.27 |
| Chronic Urticaria (Hives) | 1.3 | 1.2 | 0.08 |
| Coagulation / Micro clot triggering bacteria | 1.4 | 1 | 0.4 |
| Cognitive Function | 3.9 | 1.4 | 1.79 |
| Colorectal Cancer | 8 | 2.5 | 2.2 |
| Constipation | 1.9 | 1.6 | 0.19 |
| Coronary artery disease | 1.7 | 2.6 | -0.53 |
| COVID-19 | 9.7 | 10.8 | -0.11 |
| Crohn's Disease | 7.4 | 5.8 | 0.28 |
| Cushing's Syndrome (hypercortisolism) | 0.9 | -0.9 | |
| cystic fibrosis | 0.7 | 1.9 | -1.71 |
| d-lactic acidosis (one form of brain fog) | 0.1 | 0.1 | |
| deep vein thrombosis | 2.3 | 1.1 | 1.09 |
| Denture Wearers Oral Shifts | 0.9 | 0.9 | |
| Depression | 11.1 | 8.7 | 0.28 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 1.3 | 2.2 | -0.69 |
| Endometriosis | 2.7 | 1.5 | 0.8 |
| Eosinophilic Esophagitis | 0.6 | -0.6 | |
| Epilepsy | 2.9 | 2.4 | 0.21 |
| erectile dysfunction | 1.4 | 0.3 | 3.67 |
| Fibromyalgia | 2.9 | 2.1 | 0.38 |
| Functional constipation / chronic idiopathic constipation | 4.7 | 2.9 | 0.62 |
| gallstone disease (gsd) | 2.8 | 1.2 | 1.33 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.4 | 1.2 | 0.17 |
| Generalized anxiety disorder | 2.3 | 2.4 | -0.04 |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 1.8 | 1 | 0.8 |
| Graves' disease | 1.6 | 2.7 | -0.69 |
| Gulf War Syndrome | 0.4 | 2.3 | -4.75 |
| Halitosis | 0.9 | 0.3 | 2 |
| Hashimoto's thyroiditis | 3 | 1.6 | 0.88 |
| Heart Failure | 3.2 | 2.9 | 0.1 |
| hemorrhagic stroke | 1 | 1 | |
| Hidradenitis Suppurativa | 1.2 | 0.3 | 3 |
| High Histamine/low DAO | 0.7 | 0.3 | 1.33 |
| hypercholesterolemia (High Cholesterol) | 0.4 | 0.6 | -0.5 |
| hyperglycemia | 1.9 | 2.2 | -0.16 |
| Hyperlipidemia (High Blood Fats) | 1.3 | 0.3 | 3.33 |
| hypersomnia | 0.7 | -0.7 | |
| hypertension (High Blood Pressure | 4.4 | 5.5 | -0.25 |
| Hypothyroidism | 1.3 | 0.7 | 0.86 |
| Hypoxia | 2.7 | 0.5 | 4.4 |
| IgA nephropathy (IgAN) | 1.3 | 3.8 | -1.92 |
| Inflammatory Bowel Disease | 7.2 | 8.4 | -0.17 |
| Insomnia | 1.6 | 3.1 | -0.94 |
| Intelligence | 1.4 | 0.2 | 6 |
| Intracranial aneurysms | 0.9 | 0.6 | 0.5 |
| Irritable Bowel Syndrome | 7 | 5.1 | 0.37 |
| ischemic stroke | 2.9 | 1.7 | 0.71 |
| Liver Cirrhosis | 6.4 | 4.3 | 0.49 |
| Long COVID | 6.3 | 7.6 | -0.21 |
| Low bone mineral density | 0.8 | -0.8 | |
| Lung Cancer | 1.4 | 1.3 | 0.08 |
| Lymphoma | 0.9 | 0.9 | |
| Mast Cell Issues / mastitis | 0.9 | 0.3 | 2 |
| ME/CFS with IBS | 0.3 | 1.8 | -5 |
| ME/CFS without IBS | 1.3 | 2.4 | -0.85 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 1.8 | 1 | 0.8 |
| Metabolic Syndrome | 6.8 | 7.7 | -0.13 |
| Mood Disorders | 10.9 | 7.5 | 0.45 |
| multiple chemical sensitivity [MCS] | 1 | 0.1 | 9 |
| Multiple Sclerosis | 6.7 | 5 | 0.34 |
| Multiple system atrophy (MSA) | 1.6 | 0.4 | 3 |
| myasthenia gravis | 0.9 | 0.5 | 0.8 |
| neuropathic pain | 0.3 | 3.3 | -10 |
| Neuropathy (all types) | 1.1 | 3.1 | -1.82 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.7 | 0.7 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 4.3 | 5.2 | -0.21 |
| NonCeliac Gluten Sensitivity | 1.9 | 0.6 | 2.17 |
| Obesity | 10 | 7.5 | 0.33 |
| obsessive-compulsive disorder | 5.4 | 3 | 0.8 |
| Osteoarthritis | 2.2 | 1.3 | 0.69 |
| Osteoporosis | 2.6 | 2.2 | 0.18 |
| pancreatic cancer | 1.5 | 0.6 | 1.5 |
| Parkinson's Disease | 8.2 | 6 | 0.37 |
| Polycystic ovary syndrome | 5.2 | 2.5 | 1.08 |
| Postural orthostatic tachycardia syndrome | 0.3 | -0.3 | |
| Premenstrual dysphoric disorder | 0.7 | 0.4 | 0.75 |
| primary biliary cholangitis | 1.2 | 1 | 0.2 |
| Primary sclerosing cholangitis | 2.3 | 1.9 | 0.21 |
| Psoriasis | 3.2 | 3.2 | 0 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 6.8 | 3.8 | 0.79 |
| Rosacea | 0.3 | 0.8 | -1.67 |
| Schizophrenia | 6.5 | 2.7 | 1.41 |
| scoliosis | 0.1 | 0.9 | -8 |
| Sjögren syndrome | 2.8 | 3 | -0.07 |
| Sleep Apnea | 1.3 | 1.3 | 0 |
| Slow gastric motility / Gastroparesis | 0.7 | 0.3 | 1.33 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1 | 0.6 | 0.67 |
| Stress / posttraumatic stress disorder | 2.7 | 3 | -0.11 |
| Systemic Lupus Erythematosus | 3.5 | 2.1 | 0.67 |
| Tic Disorder | 1.2 | 1.3 | -0.08 |
| Tourette syndrome | 1.3 | 0.3 | 3.33 |
| Type 1 Diabetes | 5.1 | 3.9 | 0.31 |
| Type 2 Diabetes | 7.8 | 7.5 | 0.04 |
| Ulcerative colitis | 5.4 | 7.1 | -0.31 |
| Unhealthy Ageing | 3.9 | 2.6 | 0.5 |
| Vitiligo | 2.1 | 1.1 | 0.91 |
